In 2013, the EMA designated 4,6,4′-trimethylangelicin (TMA) as an orphan drug for the treatment of CF (EU/3/13/1137) [4] due to a triple-acting behavior toward the function of the CFTR. This evidence concerns the gene CFTR and cystic fibrosis.